Article
Dermatologists who administer chemotherapy and other drugs in their offices could see significant reductions in reimbursement levels as a result of an effort by the federal government to curtail Medicare's costs for drugs used to treat cancer.
Potential 2025 Tax Law Changes: What Dermatologists Should Know
The Cutaneous Connection: Episode 18-Cybersecurity Within the Dermatology Practice
Tips and Tricks for Successful Practice Management with Leon Kircik, MD
Success Factors for Employed Dermatologists
The Dermatology Industry Landscape: Unpacking Economic and Mergers & Acquisitions Movements
How OJM Group Can Help Dermatologists Reach Their Financial Goals in 2025 and Beyond